IL323166A - אימונותרפיה נגד אנטיגן הנוקלאוקפסיד של covid-19 באמצעות חלבוני איחוי ושיטות לשימוש - Google Patents

אימונותרפיה נגד אנטיגן הנוקלאוקפסיד של covid-19 באמצעות חלבוני איחוי ושיטות לשימוש

Info

Publication number
IL323166A
IL323166A IL323166A IL32316625A IL323166A IL 323166 A IL323166 A IL 323166A IL 323166 A IL323166 A IL 323166A IL 32316625 A IL32316625 A IL 32316625A IL 323166 A IL323166 A IL 323166A
Authority
IL
Israel
Prior art keywords
sars
fusion protein
cov
seq
protein
Prior art date
Application number
IL323166A
Other languages
English (en)
Original Assignee
Vakston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakston Inc filed Critical Vakston Inc
Publication of IL323166A publication Critical patent/IL323166A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL323166A 2023-03-06 2025-09-04 אימונותרפיה נגד אנטיגן הנוקלאוקפסיד של covid-19 באמצעות חלבוני איחוי ושיטות לשימוש IL323166A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363488565P 2023-03-06 2023-03-06
PCT/US2024/018494 WO2024186803A2 (en) 2023-03-06 2024-03-05 Nucleocapsid antigen immunotherapy for covid-19 fusion proteins and methods of use

Publications (1)

Publication Number Publication Date
IL323166A true IL323166A (he) 2025-11-01

Family

ID=92675667

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323166A IL323166A (he) 2023-03-06 2025-09-04 אימונותרפיה נגד אנטיגן הנוקלאוקפסיד של covid-19 באמצעות חלבוני איחוי ושיטות לשימוש

Country Status (6)

Country Link
EP (1) EP4676530A2 (he)
KR (1) KR20250156726A (he)
CN (1) CN120897758A (he)
AU (1) AU2024231716A1 (he)
IL (1) IL323166A (he)
WO (1) WO2024186803A2 (he)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230004508A (ko) * 2020-03-20 2023-01-06 비온테크 에스이 코로나바이러스 백신 및 사용 방법
HUE062716T2 (hu) * 2020-04-10 2023-11-28 Akston Biosciences Corp Antigénspecifikus immunterápia COVID-19 fúziós fehérjékhez és az alkalmazási eljárások
US20240082387A1 (en) * 2020-09-07 2024-03-14 Gi Cell, Inc. Fusion protein comprising coronavirus-derived receptor-binding domain and nucleocapsid protein, and use thereof

Also Published As

Publication number Publication date
KR20250156726A (ko) 2025-11-03
CN120897758A (zh) 2025-11-04
AU2024231716A1 (en) 2025-09-04
WO2024186803A3 (en) 2024-10-24
EP4676530A2 (en) 2026-01-14
WO2024186803A2 (en) 2024-09-12

Similar Documents

Publication Publication Date Title
US12343393B2 (en) Antigen specific immunotherapy for COVID-19 fusion proteins and methods of use
AU2019315602B2 (en) Nipah virus immunogens and their use
KR20230107621A (ko) 메타뉴모바이러스에 대한 단백질-기반 나노입자 백신
US20230399364A1 (en) Immunogenic Coronavirus Fusion Proteins and Related Methods
US20260035433A1 (en) Pd-l1 analog fusion proteins for antigen specific immunotherapy and methods of use
WO2021231729A1 (en) Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
IL323166A (he) אימונותרפיה נגד אנטיגן הנוקלאוקפסיד של covid-19 באמצעות חלבוני איחוי ושיטות לשימוש
EP4384534A1 (en) Truncated influenza neuraminidase and methods of using the same
TW202320845A (zh) 用於預防及治療２０１９冠狀病毒病（ＣＯＶＩＤ—１９）之ＳＡＲＳ—ＣｏＶ—２多重表位肽／蛋白質疫苗
WO2024130061A1 (en) Immunogenic ebolavirus fusion proteins and related methods
WO2024059149A2 (en) Immunogenic coronavirus fusion proteins and related methods